Skip to main content
Premium Trial:

Request an Annual Quote

Waters SARS-CoV-2 LC-MS Kit

Waters has launched the research-use-only SARS-CoV-2 LC-MS Kit, which uses an orthogonal analytical method to directly detect and quantify SARs-CoV-2 Nucleocapsid peptides. According to the company, testing has shown that researchers can achieve the analytical sensitivity required to detect and quantify low levels of three unique peptides derived from the SARS-CoV-2 NCAP protein, with data on the Xevo TQ-XS System showing a lower limit of quantitation of 3 amol/µL. Waters said this is made possible by using an anti-peptide antibody enrichment sample prep method and antibodies from SISCAPA Assay Technologies. Results can be captured with clean, low-noise chromatograms in less than two minutes per sample, Waters added. The kit has been optimized on both the Xevo system and the Acquity I-Class Plus System, the company said.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.